{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:12:08Z","timestamp":1760044328344},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":17049,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1969,5]]},"abstract":"<jats:p>A spectrophotofluorometric method for the quantitative determination of pentazocine plasma levels in man, which detects concentrations as low as 0.03 \u00b5g per milliliter is described. Following intramuscular and oral administration, plasma levels of pentazocine coincide closely with onset, duration, and intensity of analgesia, as well as with other pharmacologic effects. The mean peak plasma level after 45 mg. per 70 Kg., intramuscularly, was 0.14 p,g per milliliter. The mean peak plasma level after 75 mg. orally was 0.16 \u00b5g per milliliter, but as much as 25 per cent are biotransformation products. The plasma half\u2010life is about 2 hours after intravenous or intramuscular administration. Side effects of pentazocine may be more prominent in ambulatory subjects or in those experiencing minimal pain.<\/jats:p>","DOI":"10.1002\/cpt1969103320","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:03:37Z","timestamp":1451955817000},"page":"320-328","source":"Crossref","is-referenced-by-count":82,"title":["Relationship of pentazocine plasma levels to pharmacological activity in man"],"prefix":"10.1111","volume":"10","author":[{"given":"Barry A.","family":"Berkowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Asling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol M.","family":"Shnider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Leong","family":"Way","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1969103320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1969103320","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1969103320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:21Z","timestamp":1699363941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1969103320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1969,5]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1969,5]]}},"alternative-id":["10.1002\/cpt1969103320"],"URL":"https:\/\/doi.org\/10.1002\/cpt1969103320","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1969,5]]}}}